RecruitingNot ApplicableNCT04761328
Fear of Recurrence and Stopping Immunotherapy
Distress Associated With Stopping Immunotherapy of Cancer Patients
Sponsor
University of Pittsburgh
Enrollment
100 participants
Start Date
Aug 2, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
The study includes participants experiencing distress with regard to stopping immunotherapy and will utilize cognitive-behavioral therapy to reduce fear of recurrence, depression, and anxiety and improve quality of life.
Eligibility
Min Age: 21 Years
Inclusion Criteria3
- Age 21 years and older
- Fluent in English
- Diagnosis of cancer and history of treatment with immunotherapy
Exclusion Criteria1
- Active suicidal ideation, delusions or hallucinations
Interventions
BEHAVIORALcognitive behavioral therapy
Cognitive-behavioral therapy involves changing these erroneous cognitions and beliefs through cognitive restructuring, modification of behavior, and development of alternative coping skills.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04761328
Related Trials
CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms
NCT056630345 locations
Brief Culturally Adapted CBT for OCD
NCT072328231 location
CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD
NCT056099161 location
Novel Mental Health Therapies to Improve Military Readiness
NCT058877131 location
AI-Based Fidelity Feedback to Enhance CBT
NCT053407381 location